Last reviewed · How we verify
Intensive BP control
Intensive blood pressure control reduces cardiovascular and cerebrovascular morbidity and mortality through aggressive pharmacological management of hypertension.
Intensive blood pressure control reduces cardiovascular and cerebrovascular morbidity and mortality through aggressive pharmacological management of hypertension. Used for Hypertension management for cardiovascular risk reduction, Prevention of stroke and myocardial infarction in high-risk patients.
At a glance
| Generic name | Intensive BP control |
|---|---|
| Also known as | Enalapril-folic acid,amlodipine,hydrochlorothiazide, Lower target for reducing SBP, Control of home SBP to a target of 120mmHg |
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Intensive BP control typically involves the use of multiple antihypertensive agents (such as ACE inhibitors, ARBs, calcium channel blockers, and/or diuretics) to achieve lower blood pressure targets than standard care. This approach aims to reduce the risk of stroke, myocardial infarction, heart failure, and chronic kidney disease by maintaining stricter BP targets, often <120 mmHg systolic in high-risk populations.
Approved indications
- Hypertension management for cardiovascular risk reduction
- Prevention of stroke and myocardial infarction in high-risk patients
Common side effects
- Hypotension
- Syncope
- Acute kidney injury
- Hyperkalemia
- Fatigue
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2) (PHASE3)
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage (PHASE4)
- Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
- Early Versus Differed Arterial Catheterization in Critically Ill Patients With Acute Circulatory Failure: (NA)
- Telehealth-Enhanced Assessment and Management (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive BP control CI brief — competitive landscape report
- Intensive BP control updates RSS · CI watch RSS
- Second Affiliated Hospital of Nanchang University portfolio CI